JOP20170040B1 - مركب لخفض جلوكوز الدم - Google Patents

مركب لخفض جلوكوز الدم

Info

Publication number
JOP20170040B1
JOP20170040B1 JOP/2017/0040A JOP20170040A JOP20170040B1 JO P20170040 B1 JOP20170040 B1 JO P20170040B1 JO P20170040 A JOP20170040 A JO P20170040A JO P20170040 B1 JOP20170040 B1 JO P20170040B1
Authority
JO
Jordan
Prior art keywords
blood glucose
glucose lowering
compound
lowering compound
field
Prior art date
Application number
JOP/2017/0040A
Other languages
English (en)
Inventor
Bruce Baldwin David
Michael Beals John
Ihor Korytko Andrew
Rhodius MCLAUGHLIN Bryant
Schellenberger Volker
Original Assignee
Lilly Co Eli
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Amunix Operating Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JOP20170040B1 publication Critical patent/JOP20170040B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

يتعلق الاختراع الحالي بمجال الدواء وعلاج مرض السكري أو فرط سكر الدم في حدود ذلك المجال. بشكل أكثر تحديدًا، يتعلق الاختراع بمركب يخفض من جلوكوز الدم، تركيبات صيدلية محتوية على هذا المركب، واستخدامات علاجية لهذا المركب.
JOP/2017/0040A 2016-02-24 2017-02-09 مركب لخفض جلوكوز الدم JOP20170040B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662299131P 2016-02-24 2016-02-24

Publications (1)

Publication Number Publication Date
JOP20170040B1 true JOP20170040B1 (ar) 2021-08-17

Family

ID=58191654

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2017/0040A JOP20170040B1 (ar) 2016-02-24 2017-02-09 مركب لخفض جلوكوز الدم
JOP/2021/0201A JOP20210201A1 (ar) 2016-02-24 2021-07-27 مركب لخفض جلوكوز الدم

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0201A JOP20210201A1 (ar) 2016-02-24 2021-07-27 مركب لخفض جلوكوز الدم

Country Status (6)

Country Link
US (1) US10035839B2 (ar)
JP (1) JP6320648B1 (ar)
AR (1) AR107560A1 (ar)
JO (2) JOP20170040B1 (ar)
TW (1) TWI633116B (ar)
WO (1) WO2017146979A1 (ar)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2393828T (lt) 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
CN115260313B (zh) 2019-12-31 2023-07-18 北京质肽生物医药科技有限公司 Glp-1和gdf15的融合蛋白以及其缀合物
WO2021139744A1 (en) 2020-01-11 2021-07-15 Beijing Ql Biopharmaceutical Co., Ltd. Conjugates of fusion proteins of glp-1 and fgf21
CA3193453A1 (en) 2020-09-30 2022-04-07 Beijing Ql Biopharmaceutical Co., Ltd. Polypeptide conjugates and methods of uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
LT2393828T (lt) * 2009-02-03 2017-01-25 Amunix Operating Inc. Prailginti rekombinantiniai polipeptidai ir juos apimančios kompozicijos
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
AR090843A1 (es) * 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica

Also Published As

Publication number Publication date
JOP20210201A1 (ar) 2023-01-30
JP2018513854A (ja) 2018-05-31
WO2017146979A1 (en) 2017-08-31
TWI633116B (zh) 2018-08-21
JP6320648B1 (ja) 2018-05-09
AR107560A1 (es) 2018-05-09
US20170240614A1 (en) 2017-08-24
US10035839B2 (en) 2018-07-31
TW201738265A (zh) 2017-11-01

Similar Documents

Publication Publication Date Title
PH12019502655A1 (en) Acylated insulin compound
JOP20210201A1 (ar) مركب لخفض جلوكوز الدم
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
MX2016010899A (es) A22k, desb27, b29r, des b30 en la posicion epsilon del analogo de insulina humana acilada de lisina 22.
MX2019007119A (es) Preparado oral del activador de glucocinasa y preparacion del mismo.
NZ750174A (en) Somatostatin modulators and uses thereof
NZ757081A (en) Somatostatin modulators and uses thereof
MX2018002223A (es) Derivados de insulina novedosos y usos medicos de los mismos.
PH12019501363A1 (en) Insulin containing pharmaceutical compositions
PH12016500296A1 (en) Sodium channel modulators for the treatment of pain and diabetes
MY175669A (en) Nasal powder formulation for treatment of hypoglycemia
NZ721500A (en) Use of halogen compounds for the treatment and prevention of heart attack and ischemic injury
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
EP3597208A4 (en) PHARMACEUTICAL COMPOSITION WITH ATPIF1 FOR THE TREATMENT OF DIABETES
MX347372B (es) Uso de metformina en combinacion con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa.
MX2022014309A (es) Compuestos de insulina acilada de accion temporal prolongada.
PH12020550050A1 (en) Novel acylated insulin analogues and uses thereof
MX2018011607A (es) Sultiame para el tratamiento de apnea del sueño.
TR201902863T4 (tr) Eri̇tropoi̇eti̇n ve seftri̇akson i̇çeren farmasöti̇k bi̇r bi̇leşi̇m ve parki̇nson hastaliği demansinin tedavi̇si̇ i̇çi̇n bi̇r i̇lacin üreti̇lmesi̇nde bunun bi̇r kullanimi.
WO2016126026A3 (ko) 당뇨병 치료 조성물 및 이의 용도
BR112017025270A2 (pt) composto, composição farmacêutica, e, medicamento
WO2020018058A3 (en) The injectable micronized human insulin
PL414926A1 (pl) Zastosowanie medyczne N-podstawionych pochodnych 3-amino-4-fenylo-5-oksopirazolinokarboksamidu do wytwarzania leku
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
MX2015014269A (es) Nanomatrices de tio2 con extracto de c. obtusifolia y su usi como hipoblucemiantes.